Non-Invasive Neurotechnology Expands Beyond Labs and Into Living Rooms

Brain-Stimulation Tools Once Limited to Researchers Are Now Reaching the Public at Home Through a First-of-Its-Kind Telehealth Clinical Trial

COLUMBUS, OH, UNITED STATES — U: The Mind Company, a leader in precision non-invasive neuromodulation, is transforming how people think about brain health and cognitive performance with an AI-enhanced, at-home neurotechnology platform. Traditionally confined to academic and clinical research settings, brain-stimulation devices are now becoming accessible for everyday use. The company has just begun a first-of-its-kind, IRB-approved telehealth clinical trial that brings cutting-edge Parkinson’s treatment directly to patients’ homes, wherever they are.

U: The Mind Company’s devices work by delivering small electrical pulses to the brain through a comfortable, cap-like headset. These gentle electrical signals help regulate brain activity in targeted areas, offering a non-drug approach to supporting brain health. Think of it like a pacemaker for the brain using precisely controlled electrical stimulation to help restore normal function.

With a team comprising physicians, engineers, and researchers from institutions such as MIT, the Mayo Clinic, and Johns Hopkins University, U: The Mind Company has spent years advancing this technology. Early research and extensive safety data including over 225 trial subjects and more than 25,000 hours of collected safety information underscore the promise and reliability of this approach.

“The future of medicine is electric,” said Mohammed (Mo) Abouelsoud, Founder and CEO of U: The Mind Company. “Almost all pathological manifestations come from an electrical abnormality, as electromagnetic fields are the basis of the universe.”

“We want to provide electric medicine for the global health community. Solutions that are safe, effective, and accessible to everyone who needs them,” Mo added.

U: The Mind Company’s home platforms represent a significant shift in neurotechnology from tools primarily used in research environments to solutions that everyday individuals can safely use without clinical supervision. This innovation responds to growing public interest in non-drug approaches to cognitive support, mood regulation, and brain health optimization, offering new possibilities for those seeking alternatives to traditional therapies.

The current IRB-approved telehealth clinical trial for Parkinson’s patients is now accepting participants anywhere in the US to have the device shipped directly to their homes. No hospital visits are required. All sessions are done virtually via Google Meet or Zoom.

“This is the world’s first remote clinical trial for transcranial electrical stimulation, and we’re so proud to be innovating this right here in Ohio,” said Mo.

As the field of neurotechnology continues to evolve, U: The Mind Company remains dedicated to rigorous scientific development, consumer safety, and expanding the accessibility of advanced brain-stimulation solutions. The company’s work sits at the intersection of neuromodulation research and everyday mental wellness, marking a growing trend of precision brain health tools entering the consumer market.

To learn more about the clinical trial, visit https://uthemindclinicaltrials.com/ or https://clinicaltrials.gov/study/NCT07182058.

About U: The Mind Company

U: The Mind Company is a neurotechnology innovator headquartered in Columbus, Ohio. The company develops precision, non-invasive brain-stimulation devices designed to support brain optimization and neurological care from enhancing mental performance in healthy individuals to addressing symptoms associated with neurological and psychiatric conditions. Founded by Mohammed (Mo) Abouelsoud, U: The Mind Company brings together leaders in neuroscience, engineering, and clinical research to create safe, effective, at-home brain-stimulation solutions. For more information, visit https://uthemind.company/.

Rita Tennyson

Orca Communications

rita.tennyson@orcapr.com